Search details
1.
Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα).
Bioorg Med Chem Lett
; 30(4): 126907, 2020 02 15.
Article
in English
| MEDLINE | ID: mdl-31902710
2.
Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic Modalities.
Drug Metab Dispos
; 47(10): 1122-1135, 2019 10.
Article
in English
| MEDLINE | ID: mdl-31266753
3.
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.
Nat Cancer
; 4(6): 812-828, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37277530
4.
Design and Measurement of Drug Tissue Concentration Asymmetry and Tissue Exposure-Effect (Tissue PK-PD) Evaluation.
J Med Chem
; 65(13): 8713-8734, 2022 07 14.
Article
in English
| MEDLINE | ID: mdl-35790118
5.
Synthesis and Structure-Activity Relationship of Tetra-Substituted Cyclohexyl Diol Inhibitors of Proviral Insertion of Moloney Virus (PIM) Kinases.
J Med Chem
; 63(23): 14885-14904, 2020 12 10.
Article
in English
| MEDLINE | ID: mdl-33258605
6.
Small Molecule Dysregulation of TEAD Lipidation Induces a Dominant-Negative Inhibition of Hippo Pathway Signaling.
Cell Rep
; 31(12): 107809, 2020 06 23.
Article
in English
| MEDLINE | ID: mdl-32579935
7.
Antibody Conjugation of a Chimeric BET Degrader Enables inâ vivo Activity.
ChemMedChem
; 15(1): 17-25, 2020 01 07.
Article
in English
| MEDLINE | ID: mdl-31674143
8.
Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic.
J Med Chem
; 63(5): 2013-2027, 2020 03 12.
Article
in English
| MEDLINE | ID: mdl-31059256
9.
Applications of Quantitative Systems Pharmacology in Model-Informed Drug Discovery: Perspective on Impact and Opportunities.
CPT Pharmacometrics Syst Pharmacol
; 8(11): 777-791, 2019 11.
Article
in English
| MEDLINE | ID: mdl-31535440
10.
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
Cancer Res
; 78(6): 1537-1548, 2018 03 15.
Article
in English
| MEDLINE | ID: mdl-29343524
11.
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.
J Med Chem
; 60(12): 4869-4881, 2017 06 22.
Article
in English
| MEDLINE | ID: mdl-28557458
12.
Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.
J Med Chem
; 58(21): 8373-86, 2015 Nov 12.
Article
in English
| MEDLINE | ID: mdl-26505898
13.
Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research.
Front Pharmacol
; 5: 174, 2014.
Article
in English
| MEDLINE | ID: mdl-25120485
14.
Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
Clin Cancer Res
; 20(7): 1834-45, 2014 Apr 01.
Article
in English
| MEDLINE | ID: mdl-24474669
Results
1 -
14
de 14
1
Next >
>>